First-in-Human CLL1-CD33 Compound CAR T Cell Therapy Induces Complete Remission in Patients with Refractory Acute Myeloid Leukemia: Update on Phase 1 Clinical Trial

ConclusionOur first-in-human clinical trial demonstrates promising efficacy of cCAR therapy in treating patients with relapsed/ refractory AML. cCAR is able to eradicate leukemia blasts and leukemia stem cells, exerting a profound tumor killing effect that is superior to single target CAR T cell therapies. cCAR is also shown to induce total myeloid ablation in bone marrow, suggesting that it may act as a safer alternative to avoid the severe toxicities caused by standard bone marrow ablation regimens without sacrificing the anti-tumor efficacy. This strategy will likely benefit patients who are unable to tolerate total body radiation or high dose chemotherapies. In addition to AML, cCAR also has the potential to treat blast crisis developed from myelodysplastic syndrome, chronic myeloid leukemia, and chronic myeloproliferative neoplasm.DisclosuresPinz: iCell Gene Therapeutics LLC: Employment. Ma: iCAR Bio Therapeutics Ltd: Employment. Wada: iCell Gene Therapeutics LLC: Employment. Chen: iCell Gene Therapeutics LLC: Employment. Ma: iCell Gene Therapeutics LLC: Employment. Ma: iCell Gene Therapeutics LLC, iCAR Bio Therapeutics Ltd: Consultancy, Equity Ownership, Research Funding.

Source: Blood - November 21, 2018 Category: Hematology Authors: Liu, F., Cao, Y., Pinz, K., Ma, Y., Wada, M., Chen, K., Ma, G., Shen, J., Tse, C. O., Su, Y., Xiong, Y., He, G., Li, Y., Ma, Y. Tags: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Immunotherapy Source Type: research